Fig. 4: Functional validation of Tfdp1 and E2f4 in hematopoiesis in vivo.

A Scheme of in vivo functional validation in hematopoiesis. B Representative FACS analysis of mCherry⁺GFP⁺ (KO) and mCherry⁺GFP^- (WT) donor cells in the bone marrow (BM) and spleen of the recipients transplanted with the indicated sgRNA-treated HSPCs. C Summary of the GFP⁺/GFP^- ratios within mCherry⁺ cells in the bone marrow (BM) and spleen of recipient animals as shown in (B) (n = 3–6, technical replicates). D FACS gating strategy (left) and GFP analysis (right) in the indicated stem and progenitor cell populations: HSPC, common lymphoid progenitor (CLP), granulocyte/myeloid progenitor (GMP), common myeloid progenitor (CMP), megakaryocyte/erythroid progenitor (MEP). The used sgRNAs are indicated at the top. E Summary of the GFP⁺/GFP^- ratios calculated in (D) from different mice transplanted with sgTfdp1-infected (top) and sgE2f4-infected (bottom) HSPCs. SgRosa26 was used as a control in all experiments. F GFP⁺/GFP^- ratios in the analyzed mature immune cell lineages: T cells, natural killer (NK) cells, B cells, Gr-1 (granulocyte), and myeloid cells (CD11b⁺) isolated from bone marrow and spleen of mice transplanted with the indicated sgRNA-infected HSPCs.